Dendritic cell engineering for tumor immunotherapy: From biology to clinical translation

Immunotherapy

Volumn 4, Issue 7, 2012, Pages 703-718

  Bhargava, Arpit ^a,b   Mishra, Dinesh ^c   Banerjee, Smita ^b   Mishra, Pradyumna Kumar ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Department of Biotechnology   (India)

^c GG Central University   (India)

Author keywords

cancer therapy; cellular vaccines; molecular medicine; translational oncology

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA GALACTOSYLCERAMIDE; BACULOVIRUS VECTOR; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; DOCETAXEL; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IDIOTYPIC ANTIBODY; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LENTIVIRUS VECTOR; MUCIN 1; NANOPARTICLE; POLYGLACTIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; SIPULEUCEL T; SOLID LIPID NANOPARTICLE; SURVIVIN; TELOMERASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; WT1 PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL ENGINEERING; CELL LINE; CELL LYSATE; CELL MATURATION; CELL STRAIN LNCAP; CHEMOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; ENDOMETRIUM CANCER; GENE SILENCING; GENE TRANSFER; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYELOID DENDRITIC CELL; NANOENCAPSULATION; NONHUMAN; OVARY CANCER; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; TUMOR CELL; UNSPECIFIED SIDE EFFECT; URINARY TRACT CANCER;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL ENGINEERING; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MICROENVIRONMENT;

EID: 84864601277     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.40     Document Type: Review

References (153)

1. Dzopalic T, Rajkovic I, Dragicevic A, Colic M. The response of human dendritic cells to co-ligation of pattern-recognition receptors. Immunol. Res. 52(1-2), 20-33 (2012).
2. Kloetzel PM. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat. Immunol. 5, 661-669 (2004).
3. Burgevin A, Saveanu L, Kim Y et al. A detailed analysis of the murine TAP transporter substrate specifcity. PLoS ONE 3, e2402 (2008).
4. Link A, Vogt TK, Favre S et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 8, 1255-1265 (2007).
5. Worbs T, Förster R. A key role for CCR7 in establishing central and peripheral tolerance. Trends Immunol. 28, 274-280 (2007).
6. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7, 543-555 (2007).
7. + dendritic cells. J. Exp. Med. 207, 1273-1281 (2010).
8. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189, 587-592 (1999).
9. Pulendran B, Smith JL, Caspary G et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA 96, 1036-1041 (1999).
10. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195, 1289-1302 (2002).
11. (-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685-1696 (2000).
12. + dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
13. + dendritic cells is attributable to their ability to internalize dead cells. Immunology 107, 183-189 (2002).
14. Ouabed A, Hubert FX, Chabannes D et al. Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. J. Immunol. 180, 5862-5870 (2008).
15. Robbins SH, Walzer T, Dembele D et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profling. Genome Biol. 9, R17 (2008).
16. Fonteneau JF, Kavanagh DG, Lirvall M et al. Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 102, 4448-4455 (2003).
17. Santiago-Schwarz F, Coppock DL, Hindenburg AA, Kern J. Identifcation of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood 84, 3054-3062 (1994).
18. Chaperot L, Bendriss N, Manches O et al. Identifcation of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97, 3210-3217 (2001).
19. López JA, Bioley G, Turtle CJ et al. Single step enrichment of blood dendritic cells by positive immunoselection. J. Immunol. Methods 274, 47-61 (2003).
20. Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170, 4069-4076 (2003).
21. Mishra D, Mishra PK, Dabadghao S et al. Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine 6, 110-118 (2010).
22. + cells. Transfusion 49, 2109-2121 (2009).
23. + hematopoietic progenitors in IL-7-and IL-13-conditioned cultures. Arch. Immunol. Ther. Exp. (Warsz.) 57, 67-74 (2009).
24. Corthay A. How do regulatory T cells work? Scand. J. Immunol. 70, 326-336 (2009).
25. Nelson BH. IDO and outcomes in ovarian cancer. Gynecol. Oncol. 115, 179-180 (2009).
26. Muthuswamy R, Urban J, Lee JJ et al. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68, 5972-5978 (2008).
27. Muthuswamy R, Mueller-Berghaus J, Haberkorn U et al. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 116, 1454-1459 (2010).
28. Munn DH, Sharma MD, Baban B et al GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633-642 (2005).
29. + T regulatory cells. J. Immunol. 183, 145-154 (2009).
30. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934-5937 (2004).
31. Fujita M, Zhu X, Ueda R et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-signifcant roles of CXCL10. Cancer Res. 69, 1587-1595. (2009).
32. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995 (2004).
33. Takeda K, Akira S. TLR signaling pathways. Semin. Immunol. 16, 3-9 (2004).
34. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
35. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769-776 (2005).
36. Gautier G, Humbert M, Deauvieau F et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201, 1435-1446 (2005).
37. Warger T, Osterloh P, Rechtsteiner G et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108, 544-550 (2006).
38. Oh JZ, Kedl RM. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 185, 4602-4608 (2010).
39. Dauer M, Lam V, Arnold H et al. Combined use of Toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J. Immunol. Methods 337, 97-105 (2008).
40. Zobywalski A, Javorovic M, Frankenberger B et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl. Med. 5, 18 (2007).
41. Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mulé JJ, Riker AI. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J. Immunother. 29, 381-387 (2006).
42. + T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma. Int. J. Immunopathol. Pharmacol. 23, 35-50 (2010).
43. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J. Transl. Med. 7, 109 (2009).
44. Boullart AC, Aarntzen EH, Verdijk P et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother. 57, 1589-1597 (2008).
45. Bonehill A, Van Nuffel AM, Corthals J et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin. Cancer Res. 15, 3366-3375 (2009).
46. Stepanek I, Indrova M, Bieblova J et al Effects of 5-azacytidine and trichostatin A on dendritic cell maturation. J. Biol. Regul. Homeost. Agents 25, 517-529 (2011).
47. Roy S, Goswami S, Bose A et al. Neem leaf glycoprotein partially rectifes suppressed dendritic cell functions and associated T cell effcacy in patients with stage IIIb cervical cancer. Clin. Vaccine Immunol. 18, 571-579 (2011).
48. Carrasco J, Van Pel A, Neyns B et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 180, 3585-3593 (2008).
49. (+) T cells and monocyte/dendritic cell precursors. Cancer Res. 66, 4943-4951 (2006).
50. Kreiter S, Selmi A, Diken M et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70, 9031-9040 (2010).
51. Ying M, Zhen Q, Liu S, Gong F, Xie Y. Treatment of established colon carcinoma-bearing mice by dendritic cells pulsed with lysates of heat-treated tumor cells. Sci. China C Life Sci. 52, 831-835 (2009).
52. (+) CTL response by exosomes derived from IL-18 gene-modifed CEA-positive tumor cells. J. Mol. Med. 84, 1067-1076 (2006).
53. Zhang J, Zhang Y, Luo C, Xia Y, Chen H, Wu X. Glycosyl- phosphatidylinositol-anchored interleukin-2 expressed on tumor-derived exosomes induces antitumor immune response in vitro. Tumori 96, 452-459 (2010).
54. Tobiásová Z, Pospísilová D, Miller AM et al. In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clin. Immunol. 122, 18-27 (2007).
55. Brusa D, Garetto S, Chiorino G et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 26, 6422-6432 (2008).
56. Rossowska J, Pajtasz-Piasecka E, Szyda A, Zietara N, Dus D. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their infuence on immune response. Folia Histochem. Cytobiol. 45, 349-355 (2007).
57. (+) T cells against prostate cancer cells and defned prostate cancer-specifc epitopes. Prostate 71, 125-133 (2011).
58. Ferlazzo G, Semino C, Spaggiari GM, Meta M, Mingari MC, Melioli G. Dendritic cells effciently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int. Immunol. 12, 1741-1747 (2000).
59. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 61, 8105-8109 (2001).
60. Paktasz-Piasecka E, Indrova M. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy 2, 257-268 (2010).
61. Thumann P, Moc I, Humrich J et al. Antigen loading of dendritic cells with whole tumor cell preparations. J. Immunol. Methods 277, 1-16 (2003).
62. Koido S, Hara E, Homma S, Fujise K, Gong J, Tajiri H. Dendritic/tumor fusion cell-based vaccination against cancer. Arch. Immunol. Ther. Exp.(Warsz.) 55, 281-287 (2007).
63. Hiraoka K, Yamamoto S, Otsuru S et al. Enhanced tumor-specifc long-term immunity of hemagglutinating correction of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol. 173, 4297-4307 (2004).
64. Iinuma H, Okinaga K, Fukushima R et al. Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J. Immunol. 176, 3461-3469 (2006).
65. Simova J, Bieblova J, Janlova T, Bubeník J. Immunotherapy of HPV 16-associated tumours with tumour cell line/dendritic cell line (TC-1/DC2.4) hybrid vaccines. Folia Biol. (Praha) 49, 203-206 (2003).
66. Yasuda T, Kamigaki T, Kawasaki K et al. Superior anti-tumor protection and therapeutic effcacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 56, 1025-1036 (2007).
67. Zhou J, Xia JC, Wang H et al. Antitumor response induced by vaccine of autologous dendritic/tumor fusion cells against renal cell. Zhonghua Zhong Liu Za Zhi 29, 411-414 (2007).
68. Inzkirweli N, Gückel B, Sohn C, Wallwiener D, Bastert G, Lindner M. Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res. 27, 2121-2129 (2007).
69. Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M, Kokhaei P. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell. Immunol. 257, 23-31 (2009).
70. Ribas A, Camacho LH, Lee SM et al. Multicenter Phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J. Transl. Med. 8, 89 (2010).
71. Ying M, Zhen Q, Liu S, Gong F, Xie Y. Treatment of established colon carcinoma-bearing mice by dendritic cells pulsed with lysates of heat-treated tumor cells. Sci. China C Life Sci. 52, 831-835 (2009).
72. Gitlitz BJ, Belldegrun AS, Zisman A et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. 26, 412-419 (2003).
73. Maier T, Tun-Kyi A, Tassis A et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumorlysate-pulsed dendritic cells. Blood 102, 2338-2344 (2003).
74. Herzog GI, Solgi G, Wiegmann DS et al. Quality of tumor lysates used for pulsing dendritic cells is infuenced by the method used to harvest adherent tumor cells. BMC Res. Notes 4, 153 (2011).
75. Hatfeld P, Merrick AE, West E et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy J. Immunother. 31, 620-632 (2008).
76. Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum. Immunol. 65, 794-802 (2004).
77. Toh HC, Wang WW, Chia WK et al. Clinical beneft of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin. Cancer Res. 15, 7726-7736 (2009).
78. Lee YR, Lee YH, Im SA, Kim K, Lee CK. Formulation and characterization of antigen-loaded PLGA nanoparticles for effcient cross-priming of the antigen. Immune Netw. 11, 163-168 (2011).
79. Mishra H, Mishra D, Mishra PK, Nahar M, Dubey V, Jain NK. Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. J. Pharm. Pharm. Sci. 13, 495-509 (2010).
80. Rossowska J, Pajtasz-Piasecka E, Rysnik O et al. Generation of antitumor response by IL-2-transduced JAWS II dendritic cells. Immunobiology 216, 1074-1084 (2011).
81. Wang H, Zhang L, Kung SK. Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy. Immunotherapy 2, 685-695 (2010).
82. Suzuki T, O Chang M, Kitajima M, Takaku H. Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells. Cell. Mol. Immunol. 7, 440-446 (2010).
83. Alshamsan A, Haddadi A, Hamdy S et al. STAT3 Silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Mol. Pharm. doi:10.1021/mp100067u (2010) (Epub ahead of print).
84. + T cells. Blood 116, 4501-4511 (2010).
85. Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1-15 (2007).
86. Zhong H, Shurin MR, Han B. Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev. Vaccines 6, 333-345 (2007).
87. Nagorsen D, Thiel E. HLA typing demands for peptide-based anti-cancer vaccine. Cancer Immunol. Immunother. 57, 1903-1910 (2008).
88. Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Frelinger JA. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 164, 4961-4967 (2000).
89. Hao S, Ye Z, Yang J, Bai O, Xiang J. Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity. Cancer Biother. Radiopharm. 21, 146-154 (2006).
90. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92, 13-27 (2004).
91. + T cells against tumors. Cancer Immunol. Immunother. 57, 63-71 (2008).
92. Verdijk P, Aarntzen EH, Lesterhuis WJ et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin. Cancer. Res. 15, 2531-2540 (2009).
93. Mitsui H, Okamoto T, Kanzaki M, Inozume T, Shibagaki N, Shimada S. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity. Br. J. Dermatol. 162, 29-41 (2010).
94. Janetzki S, Britten CM, Kalos M et al. "MIATA"-minimal information about T cell assays. Immunity 31, 527-528 (2009).
95. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 55, 1524-1533 (2006).
96. Zhuang ZX, Shen LQ, Shi Y, Lu X, Shi HZ. Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer. Zhonghua Nan Ke Xue 16, 698-704 (2010).
97. Thomas-Kaskel AK, Zeiser R, Jochim R et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer 119, 2428-2434 (2006).
98. Hildenbrand B, Sauer B, Kalis O et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study. Prostate 67, 500-508 (2007).
99. Barrou B, Benoît G, Ouldkaci M et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother. 53, 453-460 (2004).
100. Katano M, Morisaki T, Koga K et al. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 25, 3771-3776 (2005).
101. Curti A, Tosi P, Comoli P et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specifc tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haematol. 139, 415-424 (2007).
102. Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol. Immunother. 55, 63-67 (2006).
103. Salcedo M, Bercovici N, Taylor R et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother. 55, 819-829 (2006).
104. Trepiakas R, Berntsen A, Hadrup SR et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a Phase I/II trial. Cytotherapy 12, 721-734 (2010).
105. Wierecky J, Müller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66, 5910-5918 (2006).
106. Berntsen A, Trepiakas R, Wenandy L et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical Phase 1/2 trial. J. Immunother. 31, 771-780 (2008).
107. Zhou J, Weng D, Zhou F et al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 58, 1587-1597 (2009).
108. Kavanagh B, Ko A, Venook A et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J. Immunother. 30, 762-772 (2007).
109. Burgdorf SK. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan. Med. Bull. 57, B4171 (2010).
110. Rahma OE, Ashtar E, Czystowska M et al. A gynecologic oncology group Phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol. Immunother. 61(3), 373-384 (2012).
111. Chu CS, Boyer J, Schullery DS et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in frst or second remission. Cancer Immunol. Immunother. 61(5), 629-641 (2012).
112. Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10, 4699-4708 (2004).
113. Vasir B, Wu Z, Crawford K et al. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J. Immunol. 181, 808-821 (2008).
114. Park MH, Yang DH, Kim MH et al. Alpha-type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic T lymphocytes against breast cancer. Cancer Res. Treat 43, 56-66 (2011).
115. Peethambaram PP, Melisko ME, Rinn KJ et al. A Phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin. Cancer Res. 15, 5937-5944 (2009).
116. Pandha HS, John RJ, Hutchinson J et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a Phase I/II study. BJU Int. 94, 412-418 (2004).
117. Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene. Ther. 13, 905-918 (2006).
118. Coosemans A, Wölf M, Berneman ZN et al. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res. 30, 3709-3714 (2010).
119. Bachleitner-Hofmann T, Friedl J, Hassler M et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol. Rep. 21, 1585-1592 (2009).
120. Motohashi S, Nagato K, Kunii N et al. A Phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol. 182, 2492-2501 (2009).
121. Okita K, Motohashi S, Shinnakasu R et al. A set of genes associated with the interferon-g response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy. Cancer Sci. 101, 2333-2340 (2010).
122. Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68, 5955-5964 (2008).
123. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer. Res. 12, 878-887 (2006).
124. Schiavoni G, Sistigu A, Valentini M et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71, 768-778 (2011).
125. Rozková D, Tiserová H, Fucíková J et al. FOCUSES on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin. Immunol. 131, 1-10 (2009).
126. Locher C, Conforti R, Aymeric L et al. Desirable cell death during anticancer chemotherapy. Ann. NY Acad. Sci. 1209, 99-108 (2010).
127. Jähnisch H, Füssel S, Kiessling A et al. Dendritic cell-based immunotherapy for prostate cancer. Clin. Dev. Immunol. 2010, 517493 (2010).
128. + self-reactive T cells. J. Immunol. 180, 4679-4686 (2008).
129. Cheng P, Corzo CA, Luetteke N et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
130. Mirza N, Fishman M, Fricke I et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299-9307 (2006).
131. Grislain L, Couvreur P, Lenaerts V et al. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15, 335-345 (1983).
132. Keijzer C, Slütter B, van der Zee R et al. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE 6, e26684 (2011).
133. Vyas SP, Khar RK. Targeted and Controlled Drug Delivery Novel Carrier Systems (1st Edition). CBS publishers and Distributors, Delhi, India, 331-386 (2002).
134. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14, 458-462 (1997).
135. Zur M, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45, 149 (1998).
136. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J. Microencapsul. 16, 205-213 (1999).
137. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 117, 1195-1203 (2007).
138. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449, 419-426 (2007).
139. Pic E, Pons T, Bezdetnaya L et al. Fluorescence imaging and whole-body bio distribution of near-infrared-emitting quantum dots after subcutaneous injection for regional lymph node mapping in mice. Mol. Imaging Biol. 12, 394-405 (2010).
140. Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants effciently drive protective T cell immunity. Eur. J. Immunol. 37, 2063-2074 (2011).
141. Bourquin C, Anz D, Zwiorek K, et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits effcient antitumoral immunity. J. Immunol. 181, 2990-2998 (2008).
142. Utoa T, Akagib T, Toyamaa M, et al. Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice. Immunol. Lett. 140, 36-43 (2011).
143. Cruz LJ, Tacken PJ, Fokkink R et al. Targeted PLGA nano-but not microparticles specifcally deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144, 118-126 (2010).
144. Tan G, Wang Z, Zhang X, Cai Z, Zhang J. Induction of CTLs by DCs pulsed with K-ras mutant peptide on the surface of nanoparticles in the treatment of pancreatic cancer. Oncol. Rep. 26, 215-221 (2011).
145. Grohmann U, Bianchi R, Orabona C et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J. Immunol. 171, 2581-2587 (2003).
146. Pedersen AE, Thorn M, Gad M et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand. J. Immunol. 61, 147-156 (2005).
147. + cytotoxic T cells with high cytolytic potential. Cancer Immunol. Immunother. 59, 1185-1195 (2010).
148. Kushibiki T, Tajiri T, Tomioka Y, Awazu K. Photodynamic therapy induces interleukin secretion from dendritic cells. Int. J. Clin. Exp. Med. 3, 110-114 (2010).
149. Shixiang Y, Xi S, Junliang L et al. Antitumor effcacy of a photodynamic therapy-generated dendritic cell glioma vaccine. Med. Oncol. 28(Suppl. 1) S453-S461 (2010).
150. Berger C, Hoffmann K, Vasquez JG et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical effcacy of extracorporeal photochemotherapy. Blood 116, 4838-4847 (2010).
151. Gao FG, Li HT, Li ZJ, Gu Jr. Nicotine stimulated dendritic cells could achieve anti-tumor effects in mouse lung and liver cancer. J. Clin. Immunol. 31, 80-88 (2011).
152. Bae WK, Umeyama A, Chung IJ, Lee JJ, Takei M. Uncarinic acid C plus IFN-g generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate. Cell. Immunol. 266, 104-110 (2010).
153. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specifc anti-tumor immunity. Nat. Biotechnol. 22, 1546-1553 (2004).